Cargando…

5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia

BACKGROUND: Tardive dyskinesia (TD) is a common side effect of antipsychotic treatment. This movement disorder consists of orofacial and limb-truncal components. The present study is aimed at investigating the role of serotonin receptors (HTR) in modulating tardive dyskinesia by genotyping patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pozhidaev, Ivan V., Paderina, Diana Z., Fedorenko, Olga Yu., Kornetova, Elena G., Semke, Arkadiy V., Loonen, Anton J. M., Bokhan, Nikolay A., Wilffert, Bob, Ivanova, Svetlana A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193905/ https://www.ncbi.nlm.nih.gov/pubmed/32390801 http://dx.doi.org/10.3389/fnmol.2020.00063

Ejemplares similares

Genes of the Glutamatergic System and Tardive Dyskinesia in Patients with Schizophrenia
por: Fedorenko, Olga Yu., et al.
Publicado: (2022)

Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia
por: Pozhidaev, Ivan V, et al.
Publicado: (2020)

PM515. The association between serotonin receptor gene polymorphisms and hyperprolactinemia in antipsychotic drug-treated schizophrenic patients
por: Ivanova, Svetlana, et al.
Publicado: (2016)

Association Study Indicates a Protective Role of Phosphatidylinositol-4-Phosphate-5-Kinase against Tardive Dyskinesia
por: Fedorenko, Olga Yu, et al.
Publicado: (2015)

Gene Polymorphisms of Hormonal Regulators of Metabolism in Patients with Schizophrenia with Metabolic Syndrome
por: Boiko, Anastasiia S., et al.
Publicado: (2022)

Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia
por: Paderina, Diana Z., et al.
Publicado: (2021)

Search for Possible Associations of FTO Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients
por: Boiko, Anastasiia S, et al.
Publicado: (2021)

Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations
por: Ivanova, Svetlana A, et al.
Publicado: (2016)

Association of ANKK1 polymorphism with antipsychotic‐induced hyperprolactinemia
por: Fedorenko, Olga Yu., et al.
Publicado: (2020)

The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia
por: Paderina, Diana Z., et al.
Publicado: (2022)

The Role of Glutamatergic Gene Polymorphisms in the Clinical Phenotypes of Schizophrenia
por: Poltavskaya, Evgeniya G., et al.
Publicado: (2023)

A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia
por: Osmanova, Diana Z., et al.
Publicado: (2019)

Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia
por: Boiko, Anastasiia S, et al.
Publicado: (2020)

Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia
por: Boiko, Anastasiia S., et al.
Publicado: (2019)

Adipocytokines and Metabolic Syndrome in Patients with Schizophrenia
por: Mednova, Irina A., et al.
Publicado: (2020)

Cytokines as Potential Biomarkers of Clinical Characteristics of Schizophrenia
por: Mednova, Irina A., et al.
Publicado: (2022)

Association between 8 P‐glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug‐induced hyperprolactinaemia
por: Geers, Lisanne M., et al.
Publicado: (2020)

Cell Adhesion Molecules in Schizophrenia Patients with Metabolic Syndrome
por: Boiko, Anastasiia S., et al.
Publicado: (2023)

Comparative Characteristics of the Metabolic Syndrome Prevalence in Patients With Schizophrenia in Three Western Siberia Psychiatric Hospitals
por: Kornetova, Elena G., et al.
Publicado: (2021)

Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome
por: Boiko, Anastasiia S., et al.
Publicado: (2022)

Levels of Acylcarnitines and Branched-Chain Amino Acids in Antipsychotic-Treated Patients with Paranoid Schizophrenia with Metabolic Syndrome
por: Mednova, Irina A., et al.
Publicado: (2022)

Limited Associations Between 5-HT Receptor Gene Polymorphisms and Treatment Response in Antidepressant Treatment-Free Patients With Depression
por: Ochi, Taichi, et al.
Publicado: (2019)

Preliminary Pharmacogenetic Study to Explore Putative Dopaminergic Mechanisms of Antidepressant Action
por: Ochi, Taichi, et al.
Publicado: (2021)

Genetic polymorphisms of PIP5K2A and course of schizophrenia
por: Poltavskaya, Evgeniya G., et al.
Publicado: (2020)

Body Fat Parameters, Glucose and Lipid Profiles, and Thyroid Hormone Levels in Schizophrenia Patients with or without Metabolic Syndrome
por: Kornetova, Elena G., et al.
Publicado: (2020)

Study of Early Onset Schizophrenia: Associations of GRIN2A and GRIN2B Polymorphisms
por: Poltavskaya, Evgeniya G., et al.
Publicado: (2021)

Amino Acid and Acylcarnitine Levels in Chronic Patients with Schizophrenia: A Preliminary Study
por: Mednova, Irina A., et al.
Publicado: (2021)

Putative role of immune reactions in the mechanism of tardive dyskinesia
por: Loonen, Anton J.M.
Publicado: (2023)

Association of rs11644461 GRIN2A with clinical phenotype of schizophrenia
por: Poltavskaya, E., et al.
Publicado: (2023)

Influence of eight ABCB1 polymorphisms on antidepressant response in a prospective cohort of treatment‐free Russian patients with moderate or severe depression: An explorative psychopharmacological study with naturalistic design
por: Geers, Lisanne M., et al.
Publicado: (2021)

Lep gene and leptin concentration in serum of schizophrenia patients with metabolic syndrome
por: Boiko, A., et al.
Publicado: (2021)

Remaining Need for In Vitro Test to Elucidate 5-Hydroxytryptamine 2C Receptor Functioning
por: Ivanova, Svetlana A., et al.
Publicado: (2018)

Genome wide study of tardive dyskinesia in schizophrenia
por: Lim, Keane, et al.
Publicado: (2021)

Igg-Dependent Hydrolysis of Myelin Basic Protein of Patients with Different Courses of Schizophrenia
por: Parshukova, Daria A., et al.
Publicado: (2020)

Catalase activity of IgG antibodies from the sera of healthy donors and patients with schizophrenia
por: Ermakov, Evgeny A., et al.
Publicado: (2017)

Copulatory Dyskinesia: Pathognomonic Manifestation of Tardive Dyskinesia
por: Sharma, Vibhash D., et al.
Publicado: (2020)

Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome
por: Kornetova, Elena G., et al.
Publicado: (2019)

METOCLOPRAMIDE IN TARDIVE DYSKINESIA
por: Hemanani, T.J., et al.
Publicado: (1983)

NMDA receptor genotypes associated with the vulnerability to develop dyskinesia
por: Ivanova, S A, et al.
Publicado: (2012)

Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics
por: Boiko, Anastasiia S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6pfn87bg7k680flj8ev2eahg1g